"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination"[nm] - Search Results

Year	Number of Results
2012	7
2013	2
2014	2
2015	7
2016	9
2017	6
2018	9
2019	3
2020	2
2021	2
2022	3
2023	1
2024	0

1

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Perry CM. Perry CM. Drugs. 2014 Jan;74(1):75-97. doi: 10.1007/s40265-013-0158-4. Drugs. 2014. PMID: 24338165 Review.

2

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review.

Naccarato MJ, Yoong DM, Fong IW, Gough KA, Ostrowski MA, Tan DHS. Naccarato MJ, et al. J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325957417752260. doi: 10.1177/2325957417752260. J Int Assoc Provid AIDS Care. 2018. PMID: 29385867 Free PMC article.

3

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.

Olin JL, Spooner LM, Klibanov OM. Olin JL, et al. Ann Pharmacother. 2012 Dec;46(12):1671-7. doi: 10.1345/aph.1R468. Epub 2012 Nov 7. Ann Pharmacother. 2012. PMID: 23136357 Review.

4

A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.

Angione SA, Cherian SM, Özdener AE. Angione SA, et al. J Pharm Pract. 2018 Apr;31(2):216-221. doi: 10.1177/0897190017710519. Epub 2017 May 30. J Pharm Pract. 2018. PMID: 28558493 Review.

5

Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.

Biagi M, Badowski ME, Chiampas T, Young J, Patel M, Vaughn P. Biagi M, et al. Int J STD AIDS. 2017 Jul;28(8):766-772. doi: 10.1177/0956462416666440. Epub 2016 Sep 1. Int J STD AIDS. 2017. PMID: 27587601

6

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.

Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á. Cid-Silva P, et al. Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):479-490. doi: 10.1111/bcpt.13161. Epub 2018 Dec 7. Basic Clin Pharmacol Toxicol. 2019. PMID: 30388308 Free article.

7

The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.

Raffe S, Fisher M. Raffe S, et al. Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):427-35. doi: 10.1517/17425255.2015.997207. Epub 2015 Jan 2. Expert Opin Drug Metab Toxicol. 2015. PMID: 25553805 Review.

8

Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.

Ramanathan S, Custodio JM, Wei X, Wang H, Fordyce M, Dave A, Ling KH, Szwarcberg J, Kearney BP. Ramanathan S, et al. J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):281-8. doi: 10.1097/QAI.0000000000000959. J Acquir Immune Defic Syndr. 2016. PMID: 26885802 Clinical Trial.

9

Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.

Malinverni S, Bédoret F, Bartiaux M, Gilles C, De Wit S, Libois A. Malinverni S, et al. Sex Transm Infect. 2021 Aug;97(5):329-333. doi: 10.1136/sextrans-2020-054714. Epub 2020 Oct 26. Sex Transm Infect. 2021. PMID: 33106437

10

Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Mayer KH, Jones D, Oldenburg C, Jain S, Gelman M, Zaslow S, Grasso C, Mimiaga MJ. Mayer KH, et al. J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):535-539. doi: 10.1097/QAI.0000000000001440. J Acquir Immune Defic Syndr. 2017. PMID: 28696345 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

45 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year